In hemodialysis patients with secondary hyperparathyroidism, an allosteric modulator of CaSR treatment is clinically recommended, because that can decrease total parathyroid volume as well as the level of intact PTH in serum30. The gene discussed is CASR; the disease is secondary hyperparathyroidism.